VIDEO: Higher-dose aflibercept meets primary endpoint in patients with DME
Click Here to Manage Email Alerts
Key takeaways:
- The PHOTON trial, which evaluated 8 mg of aflibercept in patients with diabetic macular edema, met its primary endpoint.
- Higher-dose aflibercept provided extended duration of VEGF inhibition.
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Diana V. Do, MD, discusses 48-week results from the phase 2/3 PHOTON trial.
The study evaluated the efficacy and safety of 8 mg of aflibercept in patients with diabetic macular edema.
“The PHOTON study provided some excellent data regarding the 8 mg dose of aflibercept administered every 12 or 16 weeks,” Do said. “The study met its primary endpoint, in that these higher doses of aflibercept provided extended duration of VEGF inhibition, which was clinically significant to these patients with diabetic macular edema.”
Collapse
Do DV. Aflibercept 8 mg for diabetic macular edema: 48-week results from the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; April 23-27, 2023; New Orleans.
Read more about
Click Here to Manage Email Alerts